Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 2222

1.

Epidermal growth factor receptor regulates osteoclast differentiation and survival through cross-talking with RANK signaling.

Yi T, Lee HL, Cha JH, Ko SI, Kim HJ, Shin HI, Woo KM, Ryoo HM, Kim GS, Baek JH.

J Cell Physiol. 2008 Nov;217(2):409-22. doi: 10.1002/jcp.21511.

PMID:
18543257
[PubMed - indexed for MEDLINE]
2.
3.

JNK/c-Jun signaling mediates an anti-apoptotic effect of RANKL in osteoclasts.

Ikeda F, Matsubara T, Tsurukai T, Hata K, Nishimura R, Yoneda T.

J Bone Miner Res. 2008 Jun;23(6):907-14. doi: 10.1359/jbmr.080211.

PMID:
18251700
[PubMed - indexed for MEDLINE]
4.

Activin A stimulates IkappaB-alpha/NFkappaB and RANK expression for osteoclast differentiation, but not AKT survival pathway in osteoclast precursors.

Sugatani T, Alvarez UM, Hruska KA.

J Cell Biochem. 2003 Sep 1;90(1):59-67.

PMID:
12938156
[PubMed - indexed for MEDLINE]
5.

High extracellular inorganic phosphate concentration inhibits RANK-RANKL signaling in osteoclast-like cells.

Mozar A, Haren N, Chasseraud M, Louvet L, Mazière C, Wattel A, Mentaverri R, Morlière P, Kamel S, Brazier M, Mazière JC, Massy ZA.

J Cell Physiol. 2008 Apr;215(1):47-54.

PMID:
17894387
[PubMed - indexed for MEDLINE]
6.

Critical roles of c-Jun signaling in regulation of NFAT family and RANKL-regulated osteoclast differentiation.

Ikeda F, Nishimura R, Matsubara T, Tanaka S, Inoue J, Reddy SV, Hata K, Yamashita K, Hiraga T, Watanabe T, Kukita T, Yoshioka K, Rao A, Yoneda T.

J Clin Invest. 2004 Aug;114(4):475-84.

PMID:
15314684
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

12-O-tetradecanoylphorbol-13-acetate (TPA) inhibits osteoclastogenesis by suppressing RANKL-induced NF-kappaB activation.

Wang C, Steer JH, Joyce DA, Yip KH, Zheng MH, Xu J.

J Bone Miner Res. 2003 Dec;18(12):2159-68.

PMID:
14672351
[PubMed - indexed for MEDLINE]
8.

Saurolactam inhibits osteoclast differentiation and stimulates apoptosis of mature osteoclasts.

Kim MH, Ryu SY, Choi JS, Min YK, Kim SH.

J Cell Physiol. 2009 Dec;221(3):618-28. doi: 10.1002/jcp.21892.

PMID:
19653230
[PubMed - indexed for MEDLINE]
9.

TRAF2 is essential for TNF-alpha-induced osteoclastogenesis.

Kanazawa K, Kudo A.

J Bone Miner Res. 2005 May;20(5):840-7. Epub 2004 Dec 20.

PMID:
15824857
[PubMed - indexed for MEDLINE]
10.

Epigallocatechin-3-gallate inhibits osteoclastogenesis by down-regulating c-Fos expression and suppressing the nuclear factor-kappaB signal.

Lee JH, Jin H, Shim HE, Kim HN, Ha H, Lee ZH.

Mol Pharmacol. 2010 Jan;77(1):17-25. doi: 10.1124/mol.109.057877. Epub 2009 Oct 14.

PMID:
19828731
[PubMed - indexed for MEDLINE]
Free Article
11.

Conjugated linoleic acid inhibits osteoclast differentiation of RAW264.7 cells by modulating RANKL signaling.

Rahman MM, Bhattacharya A, Fernandes G.

J Lipid Res. 2006 Aug;47(8):1739-48. Epub 2006 May 15.

PMID:
16702601
[PubMed - indexed for MEDLINE]
Free Article
12.

Calcium/calmodulin-dependent kinase activity is required for efficient induction of osteoclast differentiation and bone resorption by receptor activator of nuclear factor kappa B ligand (RANKL).

Ang ES, Zhang P, Steer JH, Tan JW, Yip K, Zheng MH, Joyce DA, Xu J.

J Cell Physiol. 2007 Sep;212(3):787-95.

PMID:
17477372
[PubMed - indexed for MEDLINE]
13.

M-CSF, TNFalpha and RANK ligand promote osteoclast survival by signaling through mTOR/S6 kinase.

Glantschnig H, Fisher JE, Wesolowski G, Rodan GA, Reszka AA.

Cell Death Differ. 2003 Oct;10(10):1165-77.

PMID:
14502240
[PubMed - indexed for MEDLINE]
Free Article
14.
15.

Infection-induced up-regulation of the costimulatory molecule 4-1BB in osteoblastic cells and its inhibitory effect on M-CSF/RANKL-induced in vitro osteoclastogenesis.

Saito K, Ohara N, Hotokezaka H, Fukumoto S, Yuasa K, Naito M, Fujiwara T, Nakayama K.

J Biol Chem. 2004 Apr 2;279(14):13555-63. Epub 2004 Jan 16.

PMID:
14729681
[PubMed - indexed for MEDLINE]
Free Article
16.

BSP and RANKL induce osteoclastogenesis and bone resorption synergistically.

Valverde P, Tu Q, Chen J.

J Bone Miner Res. 2005 Sep;20(9):1669-79. Epub 2005 May 16.

PMID:
16059638
[PubMed - indexed for MEDLINE]
17.
18.

Pyridone 6, a pan-Janus-activated kinase inhibitor, suppresses osteoclast formation and bone resorption through down-regulation of receptor activator of nuclear factor-kappaB (NF-kappaB) ligand (RANKL)-induced c-Fos and nuclear factor of activated T cells (NFAT) c1 expression.

Kwak HB, Kim HS, Lee MS, Kim KJ, Choi EY, Choi MK, Kim JJ, Cho HJ, Kim JW, Bae JM, Kim YK, Park BH, Ha H, Chun CH, Oh J.

Biol Pharm Bull. 2009 Jan;32(1):45-50.

PMID:
19122279
[PubMed - indexed for MEDLINE]
Free Article
19.

Epidermal growth factor receptor-dependent, NF-kappaB-independent activation of the phosphatidylinositol 3-kinase/Akt pathway inhibits ultraviolet irradiation-induced caspases-3, -8, and -9 in human keratinocytes.

Wang HQ, Quan T, He T, Franke TF, Voorhees JJ, Fisher GJ.

J Biol Chem. 2003 Nov 14;278(46):45737-45. Epub 2003 Sep 2.

PMID:
12952968
[PubMed - indexed for MEDLINE]
Free Article
20.

Tumor necrosis factor-alpha (TNF) stimulates RANKL-induced osteoclastogenesis via coupling of TNF type 1 receptor and RANK signaling pathways.

Zhang YH, Heulsmann A, Tondravi MM, Mukherjee A, Abu-Amer Y.

J Biol Chem. 2001 Jan 5;276(1):563-8.

PMID:
11032840
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk